Holen Sie sich die Stockscreener-App
5.81
5.89%
-0.38
Schlusskurs vom Vortag:
$6.19
Offen:
$6.14
24-Stunden-Volumen:
271.43K
Relative Volume:
0.44
Marktkapitalisierung:
$317.67M
Einnahmen:
$3.32M
Nettoeinkommen (Verlust:
$-156.76M
KGV:
-2.0021
EPS:
-2.9019
Netto-Cashflow:
$-140.13M
1W Leistung:
-10.10%
1M Leistung:
-19.65%
6M Leistung:
-27.72%
1J Leistung:
-68.06%
1-Tages-Spanne:
$5.7823
$6.20
1-Wochen-Bereich:
$5.77
$6.49
52-Wochen-Spanne:
$5.77
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
Firmenname
Upstream Bio Inc
Sektor
Branche
Telefon
781-208-2466
Adresse
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
5.80 | 339.03M | 3.32M | -156.76M | -140.13M | -2.9019 |
VRTX
Vertex Pharmaceuticals Inc
|
520.63 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
806.10 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,006.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.53 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.53 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2025-12-18 | Eingeleitet | Mizuho | Outperform |
| 2025-11-18 | Eingeleitet | Evercore ISI | Outperform |
| 2025-10-14 | Eingeleitet | Truist | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | Piper Sandler | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Upstream Bio Inc Aktie (UPB) Neueste Nachrichten
Upstream Bio (UPB) Shares Rise on Promising Trial Data, Despite High Price-to-Sales Ratio - GuruFocus
Upstream Bio Presents Results From The Phase 2 VALIANT Trial Of Verekitug For The Treatment Of Severe Asthma - marketscreener.com
A quarterly dose cut asthma flare-ups 56% versus a dummy treatment. Upstream Bio plans Phase 3 trials. - Stock Titan
Upstream Bio to present phase 2 VALIANT trial data on verekitug for severe asthma at ERS 2026 - Traders Union
Upstream Bio, Inc. (NASDAQ: UPB) Share Price, UPB Stock News, UPB Share Price & Updates - Kalkine
Why Did UPB Stock Plunge 40% Today? - stocktwits.com
Upstream Bio Outlines Phase 3 Plans for Verekitug - TipRanks
Upstream Bio on Track to Begin Two Phase 3 Verekitug Trials in Q1 2027 - marketscreener.com
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP - Stock Titan
UPB Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 5.03% EPS SurpriseStrong Earnings Momentum - vinanet.vn
Norges Bank Initiates New Position in Upstream Bio Inc (UPB) with 4.2 Million Share Purchase - GuruFocus
UPB Q1 2026 Earnings: Narrower Net Loss Beats Consensus as Pipeline Execution Takes Center StageManagement Tone Analysis - vinanet.vn
UPB Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Early-Stage PipelineMargin Compression Risk - vinanet.vn
Walleye Capital LLC Invests $3.45 Million in Upstream Bio, Inc. $UPB - MarketBeat
Upstream Bio (NASDAQ:UPB) Lowered to "Strong Sell" Rating by Wall Street Zen - MarketBeat
Upstream Bio (NASDAQ:UPB) Given New $9.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Q3 EPS Estimates for Upstream Bio Decreased by HC Wainwright - MarketBeat
Marie Sanchirico takes charge of Medical Affairs at Upstream Bio, Inc. to drive physician engagement - Traders Union
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $25 - Moomoo
H.C. Wainwright Maintains UpStream Bio(UPB.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Upstream Bio (UPB) Slides 2.54% as Biotech Caution Persists: Key Levels to WatchInstitutional Buy Signals - Vinanet
A Quick Look at Today's Ratings for UpStream Bio(UPB.US), With a Forecast Between $19 to $36 - Moomoo
Truist Financial Maintains UpStream Bio(UPB.US) With Buy Rating, Cuts Target Price to $25 - Moomoo
Upstream Bio Targets Q1 2027 Start for Phase - Minichart
Upstream Bio (NASDAQ:UPB) Announces Quarterly Earnings Results, Beats Expectations By $0.05 EPS - MarketBeat
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
UPB: Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP - TradingView
Upstream Bio posts corporate presentation highlighting verekitug Phase 3 plans in severe asthma, CRSwNP - Bitget
Pstream Bio stock rises 2.6% after Q2 results and pipeline update - Traders Union
Form 8K Upstream Bio Inc For: 11 August By Investing.com - Investing.com Canada
Upstream Bio, Inc. 2Q 2026: Revenue $0.8M, EPS $(0.73) — 10-Q Summary - TradingView
Upstream Bio (UPB) deepens R&D spend but ends quarter with $261M cash - Stock Titan
Upstream Bio Q2 net loss narrows slightly on lower R&D costs - TradingView
Upstream Bio reports Q2 2026 net loss $39.7M, cash and short-term investments $261.3M - TradingView
Upstream Bio Posts $39.7 Million Q2 Net Loss as Trials Advance - Quiver Quantitative
Upstream Bio, Inc. sets Phase 3 trial for sever asthma and CRSwNP in Q1 2027 - Traders Union
Upstream Bio (NASDAQ: UPB) reports Q2 2026 loss and advances Phase 3 plans - Stock Titan
Upstream Bio Reports Second Quarter 2026 Financial Results and Highlights Continued Progress - Caledonian Record
Upstream Bio Inc (UPB) Stock News Today - TradingKey
Upstream Bio Inc (UPB) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Upstream Bio, Inc. (UPB) Stock Analysis: A Hidden Gem in Biotechnology with a 456% Potential Upside - DirectorsTalk Interviews
Arrowstreet Capital Limited Partnership Buys New Holdings in Upstream Bio, Inc. $UPB - MarketBeat
BlackRock, Inc. Trims Stake in Upstream Bio Inc (UPB) Amid Clini - GuruFocus
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Upstream Bio (UPB) Gains Ground: Testing Key Resistance Levels After 2.5% AdvanceATR Trailing Stop - siam.in
Upstream Bio (UPB) Expected to Release Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio Inc (UPB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Upstream Bio Inc (UPB) Cash Flow - TradingKey
UPB|Upstream Bio Inc|Price:6.780|Chg%:+0.360 - TradingKey
UPB|Upstream Bio Inc|Price:6.400|Chg%:-0.010 - TradingKey
Upstream Bio Inc (UPB) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Finanzdaten der Upstream Bio Inc-Aktie (UPB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Upstream Bio Inc-Aktie (UPB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sutherland Everett Rand | Chief Executive Officer |
Jun 16 '26 |
Sale |
6.10 |
2,095 |
12,780 |
70,812 |
| Houghton Adam | Chief Business Officer |
Jun 16 '26 |
Sale |
6.10 |
700 |
4,270 |
23,601 |
| Deykin Aaron | Chief Medical Officer |
Jun 16 '26 |
Sale |
6.10 |
895 |
5,460 |
33,197 |
| Ambrose Allison | General Counsel |
Jun 16 '26 |
Sale |
6.10 |
477 |
2,910 |
16,048 |
| GRAY MICHAEL | CFO and COO |
Mar 16 '26 |
Sale |
9.29 |
852 |
7,915 |
29,648 |
| Deykin Aaron | Chief Medical Officer |
Mar 16 '26 |
Sale |
9.29 |
894 |
8,305 |
32,687 |
| Sutherland Everett Rand | Chief Executive Officer |
Mar 16 '26 |
Sale |
9.29 |
2,093 |
19,444 |
72,907 |
| Ambrose Allison | General Counsel |
Mar 16 '26 |
Sale |
9.29 |
475 |
4,413 |
16,525 |
| Houghton Adam | Chief Business Officer |
Mar 16 '26 |
Sale |
9.29 |
699 |
6,494 |
24,301 |
0.29%
4.16%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):